Report of Foreign Issuer (6-k)
09 December 2017 - 1:00AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
December 5, 2017
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X]
|
Form 40-F [ ]
|
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
Ozempic® (semaglutide)
approved in the US
Bagsværd, Denmark, 5 December
2017 -
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Ozempic® (semaglutide
injection). Ozempic
®
is indicated as an adjunct to diet and exercise to improve
glycaemic control in adults with type 2 diabetes mellitus.
Ozempic
®
,
the approved brand name for once-weekly semaglutide in the US, is a glucagon-like peptide 1 (GLP-1) receptor agonist. The approval
of Ozempic
®
is based on the results from the SUSTAIN clinical trial programme and follows
a positive recommendation from an FDA Advisory Committee meeting on 18 October 2017. In people with type 2 diabetes, Ozempic
®
produced clinically meaningful and statistically significant reductions in HbA
1c
compared
with placebo, sitagliptin, exenatide extended- release and insulin glargine U100. Furthermore, in the trials, treatment with Ozempic
®
resulted in statistically significant reductions in body weight. Ozempic
®
demonstrated
a safe and well-tolerated profile across the SUSTAIN programme with the most common adverse event being mild to moderate nausea,
which diminished over time.
Ozempic
®
is approved for use in two therapeutic dosages, 0.5 mg and 1 mg, and will be launched in the Ozempic
®
Pen, the latest generation of Novo Nordisk prefilled devices.
Novo Nordisk will, as part of the post-approval
requirements, conduct a paediatric trial in adolescents under 18 years of age and will add Ozempic
®
to the 15-year MTC (medullary thyroid carcinoma) registry that is being conducted for all other long-acting GLP-1 products.
“We are very excited
about the first approval of Ozempic
®
and look forward to making this important innovation
available to people in the US with type 2 diabetes in the beginning of 2018,” said Mads Krogsgaard Thomsen, executive vice
president and chief science officer. “Type 2 diabetes is a complex disease, but with the unique clinical profile of Ozempic
®
,
we believe it has the potential to set a new standard for the treatment of the disease.”
Page 2 of 2
Conference call
On 6 December 2017 at 12.00 pm CET, corresponding
to 6.00 am EST, a conference call for investors will be held. Investors will be able to listen in via a link on the investor section
of novonordisk.com.
About Ozempic
®
Ozempic
®
(semaglutide) is a once-weekly analogue of human glucagon-like peptide-1 (GLP-1) that has been developed for the treatment of type
2 diabetes. The review of Ozempic
®
is based on the SUSTAIN programme, a global clinical
development programme that comprises eight phase 3a trials, encompassing more than 8,000 adults with type 2 diabetes. The phase
3a programme involves a broad range of people with type 2 diabetes, including some with high cardiovascular risk profiles and people
with and without renal disease.
Ozempic
®
is currently under review by several regulatory agencies, including the European Medicines Agency and the Japanese Pharmaceuticals
and Medical Devices Agency.
Novo Nordisk is a global healthcare company with more than
90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable
us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark,
Novo Nordisk employs approximately 41,700 people in 77 countries and markets its products in more than 165 countries. Novo Nordisk's
B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information,
visit novonordisk.com
,
Facebook, Twitter, LinkedIn, YouTube
Further information
Media:
|
Katrine Sperling
|
+45 4442 6718
|
krsp@novonordisk.com
|
Ken Inchausti (US)
|
+1 609 786 8316
|
kiau@novonordisk.com
|
|
|
|
Investors
:
|
Peter Hugreffe Ankersen
|
+45 3075 9085
|
phak@novonordisk.com
|
Hanna Ögren
|
+45 3079 8519
|
haoe@novonordisk.com
|
Anders Mikkelsen
|
+45 3079 4461
|
armk@novonordisk.com
|
Christina Kjær
|
+45 3079 3009
|
cnje@novonordisk.com
|
Kasper Veje (US)
|
+1 609 235 8567
|
kpvj@novonordisk.com
|
Novo Nordisk A/S
Investor Relations
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
|
|
|
Company announcement No 90 / 2017
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: December 5, 2017
|
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer
|
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Apr 2024 to May 2024
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From May 2023 to May 2024